Welcome to our dedicated page for Sanara MedTech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanara MedTech Inc. filings document a Nasdaq-listed medical technology company focused on surgical products for wound care, wound irrigation and bone fusion. Current Reports on Form 8-K record quarterly and annual results, preliminary financial information, investor presentations, strategic priorities, material-event disclosures and exhibits tied to press releases.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation and shareholder voting. The filing record also includes disclosure categories for material agreements, capital structure, operating results and business realignment, including discontinued operations treatment for Tissue Health Plus.
DeSutter Robert Andrew reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Robert Andrew DeSutter reported receiving a grant of 5,539 shares of common stock as restricted stock, with no cash price per share. This is a compensation-related award, not an open-market purchase.
According to the filing, the restricted stock was granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan and will vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027, as long as DeSutter continues providing specified services to the company. After this grant, he directly holds 28,740 shares of Sanara MedTech common stock.
Major Eric D reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that director Eric D. Major received a grant of 4,846 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. The grant was made at no cash cost to him and increases his direct holdings to 14,232 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as Major continues providing certain services to Sanara MedTech through that date. Until vesting, the award functions as equity-based compensation tied to his ongoing service to the company.
Myers Keith G reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Keith G. Myers reported receiving a grant of 4,385 shares of common stock as restricted stock under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The award was made at no cash cost per share and increases his directly held position to 9,325 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, provided Myers continues to provide certain services to the company through that date.
Sanara MedTech Inc. has terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective immediately on June 2, 2026. The move is tied to a strategic shift toward soft tissue repair and bone fusion products for the surgical market.
The agreement, originally effective March 1, 2023, had engaged Catalyst for transaction and strategic advisory services. Catalyst is affiliated with the Company’s chairman and, with its affiliates, beneficially owns more than 5% of Sanara’s common stock. No fee or penalty was paid for the termination, and covenants on indemnification and confidentiality remain in force.
Sanara MedTech Inc. Chief Executive Officer Yon Seth D reported an automatic share withholding related to equity compensation. On the vesting of 13,466 shares of restricted stock, 3,852 shares of common stock were withheld by the company to satisfy tax withholding obligations, based on a value of $21.06 per share. No shares were issued or sold in this transaction, and following the withholding, the CEO directly holds 109,546 shares of common stock.
Sanara MedTech Inc. reported stronger results for the quarter ended March 31, 2026. Net revenue rose to $27,798,534 from $23,434,096 a year earlier, driven mainly by growth in soft tissue repair products. Gross profit increased to $25,874,945, while operating income improved to $2,646,581.
The company generated net income of $458,603, or $0.05 per diluted share, compared with a net loss of $3,527,383 in the prior-year quarter, helped by small income from discontinued THP operations. Cash declined to $13,594,459 as net cash used in operating activities was $2,465,407. Long-term debt under the CRG term loan was $46,226,422.
Sanara MedTech Inc. reported strong first quarter 2026 results with higher growth and a swing to profitability. Net revenue rose 19% to $27.8 million, driven mainly by a 21% increase in soft tissue repair product sales, while bone fusion revenue was slightly lower.
Gross profit reached $25.9 million with a 93% margin, up from 92%. Operating income more than tripled to $2.6 million. Net income from continuing operations was $0.4 million, or $0.04 per diluted share, compared with a loss a year earlier, and total net income was $0.46 million. Adjusted EBITDA increased 58% to $4.3 million, reflecting operating leverage despite higher selling and marketing costs.
Sanara ended March 31, 2026 with $13.6 million in cash and $46.2 million of long-term debt. The company guided second quarter 2026 net revenue to $28.5–$29.5 million (10–14% growth) and reaffirmed full-year 2026 net revenue guidance of $116–$121 million, implying 13–17% growth over 2025.
Mackey Ashley M reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Controller Ashley M. Mackey received a grant of 2,804 shares of restricted common stock at no cash cost under the company’s 2024 Omnibus Long-Term Incentive Plan. The restricted stock vests in three equal installments on March 22 of 2027, 2028 and 2029, if she remains employed on each date.
The amended Form 4 corrects her post‑grant holdings to 4,967 common shares, revising an earlier filing that had overstated the amount as 5,067 shares.
Sanara MedTech Inc. is holding its 2026 annual shareholder meeting virtually on June 4, 2026 at 10:00 a.m. Central Time. Holders of 9,164,757 common shares outstanding as of April 8, 2026 may vote on electing nine directors, ratifying Weaver and Tidwell, L.L.P. as auditor, and two advisory votes on executive compensation and its future frequency.
The Board recommends voting for all director nominees, for auditor ratification and say-on-pay, and selecting three years for future advisory pay votes. The proxy also details corporate governance practices, director pay in cash and restricted stock, and concentrated ownership led by Executive Chairman Ronald T. Nixon.